Media coverage about Presbia PLC (NASDAQ:LENS) has been trending positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Presbia PLC earned a news impact score of 0.26 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 44.8521324099337 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Presbia PLC (NASDAQ LENS) traded down 1.43% during trading on Thursday, reaching $2.76. The company’s stock had a trading volume of 2,655 shares. The stock’s market capitalization is $46.80 million. Presbia PLC has a 12-month low of $1.86 and a 12-month high of $4.97. The firm’s 50-day moving average is $2.53 and its 200-day moving average is $2.76.

A number of equities analysts have weighed in on the company. ValuEngine raised Presbia PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research raised Presbia PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Presbia PLC in a research report on Tuesday, May 23rd. Finally, Rodman & Renshaw decreased their target price on Presbia PLC from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $12.00.

ILLEGAL ACTIVITY WARNING: “Presbia PLC (LENS) Earning Positive Media Coverage, Study Shows” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at

About Presbia PLC

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.

Insider Buying and Selling by Quarter for Presbia PLC (NASDAQ:LENS)

Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.